Ulisse Biomed Spa
MIL:UBM
Intrinsic Value
Ulisse BioMed SpA is an Italian healthcare biotech company. [ Read More ]
The intrinsic value of one UBM stock under the Base Case scenario is 0.05 EUR. Compared to the current market price of 1.2 EUR, Ulisse Biomed Spa is Overvalued by 96%.
Valuation Backtest
Ulisse Biomed Spa
Run backtest to discover the historical profit from buying and selling UBM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ulisse Biomed Spa
Current Assets | 4.2m |
Cash & Short-Term Investments | 2.9m |
Receivables | 991.5k |
Other Current Assets | 326.1k |
Non-Current Assets | 1.5m |
Long-Term Investments | 6.1k |
PP&E | 119.8k |
Intangibles | 1.4m |
Other Non-Current Assets | 10 |
Current Liabilities | 277.4k |
Accounts Payable | 156.7k |
Other Current Liabilities | 120.7k |
Non-Current Liabilities | 421.1k |
Other Non-Current Liabilities | 421.1k |
Earnings Waterfall
Ulisse Biomed Spa
Revenue
|
90.9k
EUR
|
Cost of Revenue
|
-1.1m
EUR
|
Gross Profit
|
-967.9k
EUR
|
Operating Expenses
|
-707.6k
EUR
|
Operating Income
|
-1.7m
EUR
|
Other Expenses
|
-190
EUR
|
Net Income
|
-1.7m
EUR
|
Free Cash Flow Analysis
Ulisse Biomed Spa
UBM Profitability Score
Profitability Due Diligence
Ulisse Biomed Spa's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Ulisse Biomed Spa's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
UBM Solvency Score
Solvency Due Diligence
Ulisse Biomed Spa's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Ulisse Biomed Spa's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UBM Price Targets Summary
Ulisse Biomed Spa
According to Wall Street analysts, the average 1-year price target for UBM is 1.9 EUR .
Shareholder Return
UBM Price
Ulisse Biomed Spa
Average Annual Return | -43.28% |
Standard Deviation of Annual Returns | 36.06% |
Max Drawdown | -84% |
Market Capitalization | 26.2m EUR |
Shares Outstanding | 21 804 770 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
Officers
The intrinsic value of one UBM stock under the Base Case scenario is 0.05 EUR.
Compared to the current market price of 1.2 EUR, Ulisse Biomed Spa is Overvalued by 96%.